Oncology · Hepatocellular CarcinomaTrial Updateclinicalmid-term

Alnylam's ALN-BCAT Study in Hepatocellular Carcinoma Evaluates Safety and Efficacy

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Alnylam Pharmaceuticals1 signalView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 6:03:52 AM

Assessment confidence: 72% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing trial of ALN-BCAT in hepatocellular carcinoma could significantly impact Alnylam's oncology portfolio and competitive positioning. Positive results may lead to a new treatment option, altering market dynamics and patient care in this therapeutic area. Regulatory context from FDA (New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)) supports the near-term read. Assessment grounded in 6 ranked evidence items (4 high-relevance).

Strategic Assessment

Successful outcomes could enhance Alnylam's portfolio in oncology and provide a new treatment option for patients, potentially impacting market dynamics. The strongest clinical anchor is A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma (ClinicalTrials.gov), sub-indication match (liver cancer); entity match (alnylam pharmaceuticals). In liver cancer, 0 regulatory and 2 competitive items passed relevance filtering for Alnylam Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from MAGED4 promotes HCC progression via JAK2/STAT3 pathway activation (Humanexa Signals) — sub-indication match (liver cancer). Secondary pressure from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC).

Regulatory Outlook

Regulatory risk is concentrated around The trial's outcomes will be critical for regulatory submissions, potentially leading to new approvals that could enhance treatment options for patients with hepatocellular carcinoma..

Key Risks

Elevated medium regulatory exposure for Alnylam Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

If successful, ALN-BCAT could capture market share from existing therapies, particularly pembrolizumab, thus influencing revenue streams for Alnylam and reshaping competitive strategies in oncology.
Upside for Alnylam Pharmaceuticals may improve if A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma (ClinicalTrials.gov) delivers favorable follow-through.
Percutaneous thermal ablation is used to treat early-stage, non-resectable hepatocellular carcinoma (HCC). NK-cell immunotherapy has been studied as an adjuvant treatment, but the efficacy remains unclear when combined with ablation.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).
Successful outcomes could enhance Alnylam's portfolio in oncology and provide a new treatment option for patients, potentially impacting market dynamics.

What Would Change This Assessment

This becomes more urgent if Monitor the results of the dose escalation and expansion phases for safety data and efficacy outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
ClinicalTrials.govhigh relevance
Sub-indication match (liver cancer); Entity match (alnylam pharmaceuticals)
FDA document
View source
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Functi
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Revision Hip Prosthesis System
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

MAGED4 promotes HCC progression via JAK2/STAT3 pathway activation
Humanexa Signalsmedium relevance
Sub-indication match (liver cancer)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Study Optimizes Immunotherapy for Pancreatic Adenocarcinoma Treatment
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity
NCI's MATCH Trial Evaluates Genetic Testing for Targeted Therapy in Advanced Cancers
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity

Dual-ligand-modified cantharidin nanoparticles for the treatment of hepatocellular carcinoma via the inhibition of Ephb4.
PubMedhigh relevance
Sub-indication match (liver cancer)
FDA document
View source
High-Intensity thermal stress enhances adoptive NK-cell cytotoxicity in poorly differentiated hepatocellular carcinoma.
PubMedhigh relevance
Sub-indication match (liver cancer)
FDA document
View source
MAGED4 promotes hepatocellular carcinoma progression via activation of JAK2/STAT3 pathway by stabilizing TRIM21.
PubMedhigh relevance
Sub-indication match (liver cancer)
FDA document
View source
Comparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Opsonization and timing as key determinants of MBTA immunotherapy efficacy in pancreatic adenocarcinoma and recurrence treatment.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Alnylam Pharmaceuticals
ALN-BCAT
pembrolizumab

Commercial impact

medium

If successful, ALN-BCAT could capture market share from existing therapies, particularly pembrolizumab, thus influencing revenue streams for Alnylam and reshaping competitive strategies in oncology.

Regulatory impact

medium

The trial's outcomes will be critical for regulatory submissions, potentially leading to new approvals that could enhance treatment options for patients with hepatocellular carcinoma.

What to watch

Monitor the results of the dose escalation and expansion phases for safety data and efficacy outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.